Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 2:21 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 445 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: GLP 1 Clear all

Conditions: Obesity, Menopause
Interventions: semaglutide or tirzepatide, Lifestyle modification intervention; Drug · Behavioral
Lead sponsor: Mayo Clinic; Other
Eligibility: 46 Years to 60 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Prediabetes, Type 2 Diabetes
Interventions: Metformin, Liraglutide, Glargine, Placebo; Drug
Lead sponsor: RISE Study Group; Network
Eligibility: 20 Years to 65 Years
Enrollment: 267 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2019
U.S. locations: 4
States / cities: Chicago, Illinois • Indianapolis, Indiana • Seattle, Washington

Conditions: Drug Discontinuation, Substance Use Disorders, Eating Behavior Changes, Tirzepatide
Interventions: Discontinuation and Reinitiation of Tirzepatide; Other
Lead sponsor: The University of Texas at Dallas; Other
Eligibility: 18 Years to 70 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Pre Diabetes, Polycystic Ovary Syndrome, Obesity Android
Interventions: Liraglutide Pen Injector [Saxenda], Placebo Liraglutide Pen Injector; Drug
Lead sponsor: Woman's; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Overweight or Obesity
Interventions: Olatorepatide, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 3
States / cities: Walnut Creek, California • Winter Park, Florida • San Antonio, Texas

Conditions: Overweight, Obesity
Interventions: Semaglutide, Placebo (semaglutide), Liraglutide, Placebo (liraglutide); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 338 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 19
States / cities: Birmingham, Alabama • Fullerton, California • Huntington Beach, California + 15 more

Conditions: Blood Sugar; High, Overweight and Obesity, Fat Loss, GLP-1, Glucagon
Interventions: GB, Placebo; Dietary Supplement
Lead sponsor: Lawry Han; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 69 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Obesity
Interventions: Liraglutide, Placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 6 Years to 12 Years
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 9
States / cities: Tucson, Arizona • Denver, Colorado • Meridian, Idaho + 6 more

Conditions: Diabetes
Interventions: Glimepiride, Liraglutide; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 80 Years
Enrollment: 3,474 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Type 1 Diabetes
Interventions: Victoza, Placebo, Dapagliflozin 10mg Tab; Drug
Lead sponsor: University at Buffalo; Other
Eligibility: 18 Years to 75 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Prediabetes / Type 2 Diabetes
Interventions: Metformin, GLP-1A, MED; Drug · Dietary Supplement
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Stanford, California

Conditions: Obesity
Interventions: Cagrilintide, Semaglutide, Tirzepatide; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 809 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 46
States / cities: Birmingham, Alabama • Montgomery, Alabama • Costa Mesa, California + 39 more

Conditions: Diabetes Mellitus, Type 2
Interventions: MEDI0382 low dose, MEDI0382 mid dose, MEDI0382 high dose, Placebo, Liraglutide; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 834 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 22
States / cities: Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 17 more

Conditions: Diabetes Mellitus, Type 2
Interventions: GSK716155, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Type 2 Diabetes Mellitus, Cardiovascular Diseases
Interventions: SU, DPP4, SGLT2i, GLP-1RA, SGLT2i or GLP-1RA, Linagliptin (DPP4), Exenatide (GLP-1RA), Liraglutide (GLP-1RA), Empagliflozin (SGLT2i), Glimepiride (SU), Glipizide (SU), Glimepiride (SU) or Glipizide (SU), SU or DPP4 (excluding saxagliptin and alogliptin), Exenatide (GLP-1RA) or Liraglutide (GLP-1RA); Drug
Lead sponsor: Kaiser Permanente; Other
Eligibility: 18 Years to 85 Years
Enrollment: 241,981 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 6
States / cities: Pasadena, California • Pleasanton, California • Honolulu, Hawaii + 3 more

Conditions: Polycystic Ovarian Syndrome in Adolescent Females, Obesity (Disorder)
Interventions: GLP-1 Receptor Agonists; Drug
Lead sponsor: Nemours Children's Clinic; Other
Eligibility: 12 Years to 18 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Diabetes Mellitus, Type 2
Interventions: Albiglutide, Auto-injector; Drug · Device
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: Not listed
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 27
States / cities: Phoenix, Arizona • Fresno, California • Lomita, California + 22 more

Conditions: Obesity and Obesity-related Medical Conditions, Obesity and Overweight, Obesity Prevention, Obesity Recidivism, GLP-1, Ablation Techniques
Interventions: Gastric Fundal Mucosal Ablation (GFMA); Device
Lead sponsor: Dr. Christopher McGowan; Other
Eligibility: 21 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Cary, North Carolina

Conditions: Psoriatic Arthritis, Obesity
Interventions: Ixekizumab, Tirzepatide; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 279 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 81
States / cities: Avondale, Arizona • Chandler, Arizona • Flagstaff, Arizona + 75 more

Conditions: Type 2 Diabetes, Overweight, Cardiovascular (CV) Risk
Interventions: Tirzepatide, Dulaglutide, Semaglutide, Sitagliptin; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 887,132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Post Bariatricsurgery, Hypoglycemia
Interventions: Exendin-(9-39), Atropine, GLP-1 and GIP; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 65 Years
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2027
U.S. locations: 2
States / cities: San Antonio, Texas

Conditions: Atrial Fibrillation, Obesity
Interventions: Tirzepatide, Placebo; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 80 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Healthy
Interventions: Tirzepatide, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Obesity
Interventions: Egg breakfast (EB), Weight Loss Counseling, Weight Loss Diet, Cereal Breakfast (CB); Behavioral
Lead sponsor: Texas Tech University; Other
Eligibility: 18 Years to 44 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Lubbock, Texas

Search by objective public record fields.

Aging Well: Targeting Obesity With GLP-1 Agonists to Enhance Physical and Vascular Health in Postmenopausal Women

RISE Adult Medication Study

Clinical and Neurobehavioral Changes With Weight Loss Drug Discontinuation and Reinitiation

Liraglutide 3mg (Saxenda) on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women With PCOS

Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the US

Research Study to Investigate How Well Semaglutide Works Compared to Liraglutide in People Living With Overweight or Obesity

Glucagon Like Peptide 1 (GLP-1) Booster™ RCT Study

SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With Obesity

Replication of the LEAD-2 Diabetes Trial in Healthcare Claims Data

Effects of Single Doses of Liraglutide and Dapagliflozin on Ketogenesis in Type 1 Diabetes

Heterogeneity of Diabetes: Integrated Muli-Omics to Identify Physiologic Subphenotypes and Evaluate Targeted Prevention

A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight

A Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes

Scintigraphy Study to Assess Gastric Emptying in Healthy Subjects Given GSK716155 or Placebo.

Comparison of Type 2 Diabetes Pharmacotherapy Regimens

Effects of Glucagon-like Peptide-1 (GLP-1) Agonist in Neuro-reproductive Function in Obese Adolescent Females With Polycystic Ovary Syndrome (PCOS)

Extension to Study 200952 to Evaluate the Long-term Safety, Tolerability and Pharmacodynamics of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus Subjects

MAINTAIN (Mucosal AblatIoN Therapy After INcretins)

Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight

Comparative Effectiveness of Tirzepatide and Semaglutide in Individuals at Cardiovascular Risk

Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery

TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation

A Study of Tirzepatide (LY3298176) in Healthy Participants

High Quality Protein for Assisting With Weight Loss